Where will Moderna be in 5 years?

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Can you name a company that’s developing drugs for rare inherited illnesses, blocked arteries, and vaccines for infectious diseases you’ve never heard of? Since you clicked on this article, you already know that I’m talking about Moderna, (NASDAQ: MRNA) and not some pharma giant like Pfizer.

That’s right, by late 2025 Moderna should have its hands full with its efforts to move a selection of innovative treatments through their final clinical trials. In fact, its shareholders might be even more bullish about the company than they are today, with its coronavirus vaccine candidate on the verge of regulatory approval….